SWOG clinical trial number
CTSU/EA5181

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Open
Phase
Abbreviated Title
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Activated
04/09/2020

Research committees

Lung Cancer

Treatment

Cisplatin Carboplatin Etoposide Radiation Therapy Pemetrexed durvalumab Paclitaxel

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (http://ctsu.org) for more information and registration procedures.